|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Becker SA, Zhou YZ and Slagle BL: Frequent
loss of chromosome 8p in hepatitis B virus-positive hepatocellular
carcinomas from China. Cancer Res. 56:5092–5097. 1996.PubMed/NCBI
|
|
4
|
Baffa R, Santoro R, Bullrich F, Mandes B,
Ishii H and Croce CM: Definition and refinement of chromosome 8p
regions of loss of heterozygosity in gastric cancer. Clin Cancer
Res. 6:1372–1377. 2000.PubMed/NCBI
|
|
5
|
Johnson FB: PinX1 the tail on the
chromosome. J Clin Invest. 121:1242–1244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou XZ and Lu KP: The
Pin2/TRF1-interacting protein PinX1 is a potent telomerase
inhibitor. Cell. 107:347–359. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kondo T, Oue N, Mitani Y, Kuniyasu H,
Noguchi T, Kuraoka K, Nakayama H and Yasui W: Loss of
heterozygosity and histone hypoacetylation of the PINX1 gene are
associated with reduced expression in gastric carcinoma. Oncogene.
24:157–164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim MS, Kim SS, Yoo NJ and Lee SH: Somatic
mutation of PINX1 gene is rare in common solid cancers. APMIS.
120:770–771. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma Y, Wu L, Liu C, Xu L, Li D and Li JC:
The correlation of genetic instability of PINX1 gene to
clinico-pathological features of gastric cancer in the Chinese
population. J Cancer Res Clin Oncol. 135:431–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi M, Cao M, Song J, Liu Q, Li H, Meng F,
Pan Z, Bai J and Zheng J: PinX1 inhibits the invasion and
metastasis of human breast cancer via suppressing NF-κB/MMP-9
signaling pathway. Mol Cancer. 14:662015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li HL, Han L, Chen HR, Meng F, Liu QH, Pan
ZQ, Bai J and Zheng JN: PinX1 serves as a potential prognostic
indicator for clear cell renal cell carcinoma and inhibits its
invasion and metastasis by suppressing MMP-2 via NF-κB-dependent
transcription. Oncotarget. 6:21406–21420. 2015.PubMed/NCBI
|
|
12
|
Cai MY, Zhang B, He WP, Yang GF, Rao HL,
Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, et al: Decreased
expression of PinX1 protein is correlated with tumor development
and is a new independent poor prognostic factor in ovarian
carcinoma. Cancer Sci. 101:1543–1549. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weiser MR: AJCC 8th Edition: Colorectal
Cancer. Ann Surg Oncol. 25:1454–1455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin LL, Chung CM, Chen J, Fok KL, Ng CP,
Jia RR, Ren X, Zhou J, Zhang T, Zhao XH, et al: A suppressor of
multiple extracellular matrix-degrading proteases and cancer
metastasis. J Cell Mol Med. 13:4034–4041. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
DeClerck YA, Mercurio AM, Stack MS,
Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF,
Noel A, et al: Proteases, extracellular matrix, and cancer: A
workshop of the path B study section. Am J Pathol. 164:1131–1139.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karin M, Cao Y, Greten FR and Li ZW: NF-κB
in cancer: From innocent bystander to major culprit. Nat Rev
Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Abbruzzese JL, Evans DB and Chiao
PJ: Overexpression of urokinase-type plasminogen activator in
pancreatic adenocarcinoma is regulated by constitutively activated
RelA. Oncogene. 18:4554–4563. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takeshita H, Yoshizaki T, Miller WE, Sato
H, Furukawa M, Pagano JS and Raab-Traub N: Matrix metalloproteinase
9 expression is induced by Epstein-Barr virus latent membrane
protein 1 C-terminal activation regions 1 and 2. J Virol.
73:5548–5555. 1999.PubMed/NCBI
|
|
19
|
Bond M, Fabunmi RP, Baker AH and Newby AC:
Synergistic upregulation of metalloproteinase-9 by growth factors
and inflammatory cytokines: An absolute requirement for
transcription factor NF-kappa B. FEBS Lett. 435:29–34. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duffy MJ: The biochemistry of metastasis.
Adv Clin Chem. 32:135–166. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Price JT, Bonovich MT and Kohn EC: The
biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol.
32:175–253. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu X, Wang Y, Chen Z, Sternlicht MD,
Hidalgo M and Steffensen B: Matrix metalloproteinase-2 contributes
to cancer cell migration on collagen. Cancer Res. 65:130–136.
2005.PubMed/NCBI
|
|
23
|
Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS,
Di GH, Liu G, Li FM, Ou ZL, et al: Prognostic value of matrix
metalloproteinases (MMP-2 and MMP-9) in patients with lymph
node-negative breast carcinoma. Breast Cancer Res Treat. 88:75–85.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng
J, Zhao Q and Wang W: Matrix metalloproteinase-9 is associated with
relapse and prognosis of patients with colorectal cancer. Ann Surg
Oncol. 19:318–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Langers AM, Verspaget HW, Hawinkels LJ,
Kubben FJ, van Duijn W, van der Reijden JJ, Hardwick JC, Hommes DW
and Sier CF: MMP-2 and MMP-9 in normal mucosa are independently
associated with outcome of colorectal cancer patients. Br J Cancer.
106:1495–1498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brew K, Dinakarpandian D and Nagase H:
Tissue inhibitors of metalloproteinases: Evolution, structure and
function. Biochim Biophys Acta. 1477:267–283. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lambert E, Dassé E, Haye B and Petitfrère
E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol.
49:187–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma J, Mi C, Wang KS, Lee JJ and Jin X:
Zinc finger protein 91 (ZFP91) activates HIF-1α via NF-κB/p65 to
promote proliferation and tumorigenesis of colon cancer.
Oncotarget. 7:36551–36562. 2016.PubMed/NCBI
|
|
29
|
Lee WR, Chung CL, Hsiao CJ, Chou YC, Hsueh
PJ, Yang PC, Jan JS, Cheng YW and Hsiao G: Suppression of matrix
metalloproteinase-9 expression by andrographolide in human
monocytic THP-1 cells via inhibition of NF-κB activation.
Phytomedicine. 19:270–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jianfeng D, Feng J, Chaoneng J, Zhongzhou
Z, Shaohua G, Qihan W, Liu W, Gang Y, Yi X and Mao Y: Cloning of
the correct full length cDNA of NF-kappaB-repressing factor. Mol
Cells. 16:397–401. 2003.PubMed/NCBI
|
|
31
|
Nourbakhsh M and Hauser H: Constitutive
silencing of IFN-beta promoter is mediated by NRF (NF-kappa
B-repressing factor), a nuclear inhibitor of NF-kappa B. EMBO J.
18:6415–6425. 1999. View Article : Google Scholar : PubMed/NCBI
|
